Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Diagnostics Closes $13M Financing Investment

NEW YORK – Interpace Diagnostics said today that it has closed on a $13 million convertible preferred stock investment by Ampersand Capital Partners. 

The Parsippany, New Jersey-based company noted that the investment is the second tranche of the $27 million convertible preferred stock financing provided by Ampersand to finance Interpace's acquisition of Cancer Genetics' biopharma business in July. 

According to Interpace, about $6 million of the financing will be used to pay down a note due to Cancer Genetics in connection with the acquisition. 

"We are excited to strengthen our partnership with Ampersand and to reinforce it through overwhelming support from our shareholders as we received approval for the second tranche financing," Interpace CEO Jack Stover said in a statement.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.